Physician profile
Robert V Higgins
NPI 1063429322
$1,276.43
in general payments reported to CMS, 2019-2025
29 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $171 · 2022: $27.94 · 2023: $279 · 2024: $379 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,077.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,077.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $140.00 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $125.01 | 2021 | |
| Daiichi Sankyo INC. | $119.42 | 2024-2025 | Enhertu, Vanflyta |
| Biotissue Holdings INC. | $118.20 | 2024 | |
| Abbvie INC. | $105.51 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $67.45 | 2023-2024 | Keytruda, Lynparza |
| Alexion Pharmaceuticals, INC. | $59.20 | 2021-2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $48.94 | 2022-2025 | Lynparza |
| Medical Device Business Services, INC. | $40.46 | 2024 | Echelon Flex |
| Incyte Corporation | $39.57 | 2023 | Jakafi |
| Novartis Pharmaceuticals Corporation | $35.42 | 2024-2025 | |
| Fennec Pharmaceuticals, INC. | $27.97 | 2024 | Pedmark |
| Spectrum Pharmaceuticals INC. | $26.94 | 2025 | Rolvedon |
| Aveo Pharmaceuticals, INC. | $26.26 | 2023 | Fotivda |
| Eisai INC. | $25.42 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $24.82 | 2023 | Imbruvica |
| Ipsen Biopharmaceuticals, INC | $22.85 | 2021 | |
| Corcept Therapeutics | $22.32 | 2025 | Korlym |
| Exelixis INC. | $21.21 | 2023 | Cabometyx |
| Acrotech Biopharma INC. | $21.13 | 2023 | Beleodaq |
| Karyopharm Therapeutics INC. | $19.27 | 2023 | Xpovio |
| Janssen Biotech, INC. | $19.06 | 2023 | Erleada |
| Mallinckrodt Hospital Products INC. | $18.59 | 2025 | Acthar |
| Sobi, INC | $18.45 | 2024 | |
| Servier Pharmaceuticals LLC | $18.30 | 2024 | |
| Emd Serono, INC. | $17.99 | 2025 | |
| Amgen INC. | $16.72 | 2023 | Kyprolis |
| Genentech USA, INC. | $15.39 | 2023 | Tecentriq, Avastin, Rozlytrek |
| Morphosys, US INC. | $14.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.